Maria T. Clarke

Maria T. Clarke

Auto-generated profile, based on publicly available information

Maria T. Clarke

Department of Surgery, University of California, San Francisco, San Francisco, CA 94143, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
BBBeltran Borges
Beltran Borges
SBStephen Brown
Stephen Brown
WCWan-Jin Chen
Wan-Jin Chen
MCMaria T. Clarke
Maria T. Clarke
AHAkos Herzeg
Akos Herzeg
CSCharlotte J. Sumner
Charlotte J. Sumner
Neurological disorders with onset before or at birth are a leading cause of morbidity and mortality in infants and children. Prenatal treatment has the potential to reduce or prevent irreversible neuronal loss and facilitate normal neurodevelopment. We hypothesized that antisense oligonucleotides (ASOs) delivered to the amniotic fluid by intra-amniotic (IA) injection could safely distribute to the fetal central nervous system (CNS) and provide therapeutic benefit in the motor neuron disease spinal muscular atrophy (SMA), caused by mutations of the survival of motor neuron 1 gene ( SMN1 ), leading to deficiency of SMN protein. Although the splice-switching ASO nusinersen ameliorates SMA when delivered postnatally, substantial deficits can remain in severely affected infants. Here, IA injection of ASOs into two mouse models of severe SMA increased SMN expression in the CNS. In SMAΔ7 mice, which manifest pathology in utero, prenatal treatment improved motor neuron numbers, motor axon development, motor behavioral tests, and survival when compared with those in mice treated postnatally (between P1 and P3). To assess the feasibility of prenatal treatment in a large-animal model, ASOs were delivered midgestation to fetal sheep by IA or intracranial injection. ASOs delivered by IA injection distributed to the spinal cord at therapeutic concentrations and to multiple peripheral tissues without evidence of substantial toxicity to the fetus or mother. These data demonstrated that IA delivery of ASOs holds potential as a minimally invasive approach for prenatal treatment of SMA and possibly other severe, early-onset neurological disorders.

1 January 2022 in Rare Disease and Orphan Drugs Journal
Verified
Journal Article
Open access
PDF file
VMVikas Munjal
Vikas Munjal
MCMaria T. Clarke
Maria T. Clarke
JVJoshua Vignolles-Jeong
Joshua Vignolles-Jeong
JVJasmine A. Valencia
Jasmine A. Valencia
MTMeika Travis
Meika Travis
LSLluís Samaranch
Lluís Samaranch
Rare Disease and Orphan Drugs Journal (RDODJ) is an international, peer-reviewed, open access journal. RDODJ will report on scientific advances in the genetics of rare diseases, the molecular basis of the pathologies, and translational research on diagnosis, prevention and treatment. In addition, RDODJ aims to provide a forum for scientific studies and discussion covering the important regulatory, socio-economic and human science issues related to rare diseases and orphan drugs.